An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Waldenström Macroglobulinemia (WM)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 107 (final count)
- Started
- Sep 11, 2014
- Main results expected
- Oct 1, 2019
- Fully finished
- Dec 31, 2026
- Results posted
- Apr 24, 2020
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 6th Criteria
Measured over: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Overall Response Rate (ORR) of Acalabrutinib in Subjects as Assessed by Investigator Per IWWM 3rd Criteria
Measured over: Up to approximately 3.8 years. Data cut at when last patient has completed Cycle 27 (28 days per Cycle).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02180724 · record last updated 2026-09-14 · checked 2026-11-09 15:47 UTC